A novel model for Ki67 assessment in breast cancer

Diagnostic Pathology

Volumn 9, Issue 1, 2014, Pages

  Romero, Quinci ^a   Bendahl, Pär Ola ^a   Fernö, Mårten ^a   Grabau, Dorthe ^c   Borgquist, Signe ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Breast cancer; Counting strategy; Ki67; Proliferation; Statistical model

Indexed keywords

KI 67 ANTIGEN;

BIOPSY; BREAST NEOPLASMS; CELL COUNT; CELL PROLIFERATION; CHEMISTRY; COMPARATIVE STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; OBSERVER VARIATION; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; REPRODUCIBILITY; RETROSPECTIVE STUDY; STATISTICAL MODEL;

BIOPSY; BREAST NEOPLASMS; CELL COUNT; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MODELS, STATISTICAL; OBSERVER VARIATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES;

EID: 84903142118     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-9-118     Document Type: Article

References (27)

1. Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer 2010, 17:R245-R262. 10.1677/ERC-10-0136, 20647302.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. 10.1016/j.cell.2011.02.013, 21376230.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
4. Hilsenbeck SG, Clark GM, McGuire WL. Why do so many prognostic factors fail to pan out?. Breast Cancer Res Treat 1992, 22:197-206. 10.1007/BF01840833, 1391986.
5. van Diest PJ, van der Wall E, Baak JP. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol 2004, 57:675-681. 10.1136/jcp.2003.010777, 1770351, 15220356.
6. Ross JS, Linette GP, Stec J, Clark E, Ayers M, Leschly N, Symmans WF, Hortobagyi GN, Pusztai L. Breast cancer biomarkers and molecular medicine. Expert Rev Mol Diagn 2003, 3:573-585. 10.1586/14737159.3.5.573, 14510178.
7. Viale G. Pathological work up of the primary tumor: getting the proper information out of it. Breast 2011, 20(Suppl 3):S82-S86.
8. Thor AD, Liu S, Moore DH, Edgerton SM. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol 1999, 17:470-477.
9. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983, 31:13-20. 10.1002/ijc.2910310104, 6339421.
10. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984, 133:1710-1715.
11. Lopez F, Belloc F, Lacombe F, Dumain P, Reiffers J, Bernard P, Boisseau MR. Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes. Cytometry 1991, 12:42-49. 10.1002/cyto.990120107, 1999122.
12. Bullwinkel J, Baron-Luhr B, Ludemann A, Wohlenberg C, Gerdes J, Scholzen T. Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells. J Cell Physiol 2006, 206:624-635. 10.1002/jcp.20494, 16206250.
13. Rahmanzadeh R, Huttmann G, Gerdes J, Scholzen T. Chromophore-assisted light inactivation of pKi-67 leads to inhibition of ribosomal RNA synthesis. Cell Prolif 2007, 40:422-430. 10.1111/j.1365-2184.2007.00433.x, 17531085.
14. Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J, Gerdes J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992, 168:357-363. 10.1002/path.1711680404, 1484317.
15. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312. 10.1200/JCO.2007.14.2364, 17954709.
16. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011, 103:1656-1664. 10.1093/jnci/djr393, 3216967, 21960707.
17. Romero Q, Bendahl PO, Klintman M, Loman N, Ingvar C, Ryden L, Rose C, Grabau D, Borgquist S. Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies. BMC Cancer 2011, 11:341. 10.1186/1471-2407-11-341, 3163632, 21819622.
18. McCormick D, Yu C, Hobbs C, Hall PA. The relevance of antibody concentration to the immunohistological quantification of cell proliferation-associated antigens. Histopathology 1993, 22:543-547. 10.1111/j.1365-2559.1993.tb00174.x, 8102614.
19. Boon ME. Microwave-antigen retrieval: the importance of pH of the retrieval solution for MIB-1 staining. Eur J Morphol 1996, 34:375-379. 10.1076/ejom.34.5.0375, 9034793.
20. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005, 23:7212-7220. 10.1200/JCO.2005.07.501, 16192605.
21. de Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007, 96:1504-1513. 10.1038/sj.bjc.6603756, 2359936, 17453008.
22. Viale G. The current state of breast cancer classification. Ann Oncol 2012, 23(Suppl 10):x207-x210. 10.1093/annonc/mds326, 22987963.
23. Kayser K, Schultz H, Goldmann T, Gortler J, Kayser G, Vollmer E. Theory of sampling and its application in tissue based diagnosis. Diagn Pathol 2009, 4:6. 10.1186/1746-1596-4-6, 2649041, 19220904.
24. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010, 11:174-183. 10.1016/S1470-2045(09)70262-1, 20152769.
25. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 2008, 17:323-334. 10.1016/j.breast.2008.02.002, 18455396.
26. Mohammed ZM, McMillan DC, Elsberger B, Going JJ, Orange C, Mallon E, Doughty JC, Edwards J. Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. Br J Cancer 2012, 106:383-388. 10.1038/bjc.2011.569, 3261670, 22251968.
27. Fasanella S, Leonardi E, Cantaloni C, Eccher C, Bazzanella I, Aldovini D, Bragantini E, Morelli L, Cuorvo LV, Ferro A, Gasperetti F, Berlanda G, Dalla Palma P, Barbareschi M. Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies. Diagn Pathol 2011, 6(Suppl 1):S7. 10.1186/1746-1596-6-S1-S7, 3073225, 21489202.